Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease

References

• Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009;50:S412–6.
   PubMed Web of Science ®Google Scholar
• Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005;50:171–80.
   PubMed Web of Science ®Google Scholar
• Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 2009;8:S18–24.
   PubMed Web of Science ®Google Scholar
• Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 2009;116:539–64.
   PubMed Web of Science ®Google Scholar
• Grønbaek H, Thomsen KL, Rungby J, Schmitz O, Vilstrup H. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol 2008;2:705–11.
   PubMedGoogle Scholar
• Yilmaz Y, Ulukaya E, Gul OO, Arabul M, Gul CB, Atug O, Oral AY, Aker S, Dolar E. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009;42:802–7.
   PubMedGoogle Scholar
• Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 2009;88:1–17.
   PubMed Web of Science ®Google Scholar
• Dovio A, Data V, Angeli A. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? J Endocrinol Invest 2005;28(10 Suppl):14–22.
   PubMedGoogle Scholar
• Zdzisińska B, Bojarska-Junak A, Walter-Croneck A, KandeferSzerszeń M. Dysregulation of the receptor activator of NFkappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients’ bone marrow stromal cells co-cultured with myeloma cells. Arch Immunol Ther Exp (Warsz) 2010;58:153–63.
   PubMed Web of Science ®Google Scholar
• Chamoux E, Houde N, L’Eriger K, Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol 2008;216:536–42.
   PubMed Web of Science ®Google Scholar
• Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M, Hofbauer LC. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem 2009;108:106–16.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 – the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 2009;30:1103–9.
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005;10:3093–9.
   PubMed Web of Science ®Google Scholar
• Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:370–9.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 2009;15:4387–91.
   PubMed Web of Science ®Google Scholar
• Ugur-Altun B, Altun A, Gerenli M, Tugrul A. The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. Diabetes Res Clin Pract 2005;68:217–22.
   PubMedGoogle Scholar
• Ugur-Altun B, Altun A. Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women. Arch Med Res 2007;38:891–6.
   PubMedGoogle Scholar
• An JJ, Han DH, Kim DM, Kim SH, Rhee Y, Lee EJ, Lim SK. Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med J 2007;48:765–72.
   PubMed Web of Science ®Google Scholar
• ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care 2006;29:1955–62.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–8.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–21.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, Habior A, Graziadei I, Vogel W, Tilg H. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 2005;43:973–83.
   PubMed Web of Science ®Google Scholar
• Fábrega E, Orive A, García-Suarez C, García-Unzueta M, Antonio Amado J, Pons-Romero F. Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver Int 2005;25:305–10.
   PubMed Web of Science ®Google Scholar
• García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De la Vega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A, Gómez-Rodríguez Mde L. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol 2006;41:261–6.
   PubMed Web of Science ®Google Scholar
• Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnok E, Dunkel K, Lakatos P. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 2003;38:395–400.
   PubMed Web of Science ®Google Scholar
• Yin XM, Ding WX. Death receptor activation-induced hepatocyte apoptosis and liver injury. Curr Mol Med 2003;3:491–508.
   PubMedGoogle Scholar
• Emanuele E, Peros E, Scioli GA, D’Angelo A, Olivieri C, Montagna L, Geroldi D. Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. Int J Mol Med 2004;13:849–53.
   PubMedGoogle Scholar
• Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005;182:175–80.
   PubMed Web of Science ®Google Scholar
• Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008;48:2086–7.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Ulukaya E, Dolar E. A ‘biomarker biopsy’ for the diagnosis of NASH: promises from CK-18 fragments. Obes Surg 2008;18:1507–8.
   PubMedGoogle Scholar